2024 年半年度报告 公司代码：688363 公司简称：华熙生物 华熙生物科技股份有限公司 2024 年半年度报告 1 / 217 2024 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司生产经营构成实质性影响的重大风险。公司已于本报告中详细描述 了生产经营中面临的有关风险，详见本报告第三节"管理层讨论与分析"中关于公司风险因素的 相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人赵燕、主管会计工作负责人汪卉及会计机构负责人（会计主管人员）田涛声明： 保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成本公司对投资者的承诺，敬请投 资者注意投资风险。 九、 是否存在 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% relative to the industry index within the next six months [12]. Core Views - The company experienced a decline in revenue and net profit in 2023 due to adjustments in its skincare product line, but a significant recovery in performance is anticipated in Q1 2024 [6][8]. - The company is recognized as a global leader in biotechnology and bioactive materials, with a comprehensive value chain in hyaluronic acid production [6][8]. - The report forecasts EPS for 2024, 2025, and 2026 to be 1.71, 2.11, and 2.61 CNY respectively, with corresponding P/E ratios of 37.0X, 29.9X, and 24.3X [6][8]. Financial Summary - In 2023, the company reported revenue of 6,076 million CNY, a year-on-year decrease of 4.45%, and a net profit of 593 million CNY, down 38.97% [2][3]. - The gross margin for 2023 was 73.32%, a decline of 3.67 percentage points from the previous year, while the net margin was 9.59%, down 5.53 percentage points [3][8]. - The first quarter of 2024 showed a revenue increase of 4.24% year-on-year, with a net profit growth of 21.39% [2][3]. Business Performance - The company operates multiple business segments, with significant revenue contributions from raw materials, medical terminal products, and functional skincare products [3][6]. - The revenue from raw materials was 1,129 million CNY, up 15.22%, while medical terminal products saw a remarkable increase of 58.95% to 1,090 million CNY [3][6]. - The company has established a robust distribution network across over 70 countries, with a strong customer base of more than 4,000 global clients [3][6]. Future Outlook - The report indicates that the company is expected to benefit from the release of new production capacity, which will enhance the gross margin of its raw materials business [6][8]. - The expansion of skincare brands is anticipated to yield positive results, with potential for further optimization of expenses [6][8].

Financial Performance - In 2023, the company achieved a net profit attributable to shareholders of RMB 592,555,911.37, with a parent company net profit of RMB 709,303,002.90[5]. - The proposed cash dividend distribution is RMB 3.80 per 10 shares, totaling RMB 181,882,448.74, which accounts for 30.69% of the net profit attributable to shareholders[5]. - The company's operating revenue for 2023 was approximately CNY 6.08 billion, a decrease of 4.45% compared to CNY 6.36 billion in 2022[25]. - Net profit attributable to shareholders decreased by 38.97% to CNY 592.56 million in 2023 from CNY 970.92 million in 2022[25]. - Basic earnings per share fell by 39.11% to CNY 1.23 in 2023, down from CNY 2.02 in 2022[26]. - The company's total assets decreased by 2.44% to CNY 8.47 billion at the end of 2023, compared to CNY 8.68 billion at the end of 2022[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 490.48 million, a decrease of 42.44% from CNY 852.14 million in 2022[25]. - The comprehensive gross margin for the reporting period was 73.32%, indicating a stable production and sales situation[161]. Operational Efficiency - The net cash flow from operating activities increased by 10.15% to CNY 699.65 million in 2023, compared to CNY 635.19 million in 2022[25]. - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company has received a standard unqualified audit opinion from its auditor, Deloitte[5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not experienced any instances where more than half of the board members could not guarantee the accuracy and completeness of the annual report[9]. - The company has established a comprehensive quality management system, certified by multiple international standards, ensuring high production standards that meet cGMP and GMP requirements[145]. Research and Development - Research and development expenses accounted for 7.35% of operating revenue in 2023, an increase from 6.10% in 2022[26]. - Total R&D expenditure reached approximately CNY 44.63 million, a 14.98% increase from the previous year, representing 7.35% of total revenue[110]. - The company is actively developing 132 R&D projects in raw materials and synthetic biology, focusing on innovative green manufacturing technologies[112]. - The company has initiated 99 medical device R&D projects, with plans to launch multiple products in orthopedics, ophthalmology, and surgery over the next 1-3 years[113]. - The company has launched 1 new key research project in 2023 focused on non-animal sourced chondroitin sulfate, and continues to work on 4 national key research projects related to biomanufacturing technologies[101]. - The company has established deep collaborations with independent institutions to advance efficacy testing for new products, enhancing market competitiveness[117]. Market Expansion and Product Development - The company is focusing on digital transformation, organizational capability enhancement, compliance management, and cost reduction to drive sustainable growth[38]. - The company is expanding its distribution channels, adding coverage to over 3,500 medical institutions in the domestic market during the reporting period[43]. - The company is the exclusive distributor of RegenLab's PRP product in China, promoting it across various medical departments[64]. - The company is exploring the application of new food ingredients like sodium hyaluronate and GABA in health foods, enhancing the health quality of the population[80]. - The company is actively pursuing new strategies in biotechnology and synthetic biology to enhance its product offerings and market competitiveness[120][121]. - The company is expanding its market presence in the cosmetic sector with high molecular weight hyaluronic acid products, targeting skincare, hair care, and makeup applications[200]. Strategic Initiatives - The company is undergoing comprehensive management reforms to improve operational efficiency and adapt to changing market conditions[37]. - The company has established an ESG management system and formed an ESG strategic management center to enhance sustainable development efforts[58]. - The company has signed a strategic cooperation agreement with Jiangnan University in February 2023 to promote research in synthetic biology and human milk oligosaccharide biomanufacturing[52]. - The company is focused on the development of technologies that improve the delivery and stability of active ingredients in skincare products, addressing consumer absorption challenges[116]. - The company is committed to sustainability in its production processes, aligning with industry trends towards eco-friendly and natural ingredients[200]. Risks and Challenges - The company faces risks related to new product development, registration, and potential technology substitution, which could impact its market competitiveness[154]. - The company is exposed to supply chain management risks as it expands its business scale, necessitating effective supplier partnerships[159]. - The company’s overseas sales accounted for 13.47% of total revenue, exposing it to global economic fluctuations and trade tensions[164]. - The company is at risk of declining net profit margins due to increased strategic investments in brand building and talent acquisition[160]. - The company has implemented measures to protect its core technologies, but risks of leakage remain if confidentiality protocols are not effectively enforced[156].

Financial Performance - The company's operating revenue for Q1 2024 was RMB 1,360,531,915, representing a year-on-year increase of 4.24%[4] - The net profit attributable to shareholders was RMB 243,367,321.40, reflecting a year-on-year growth of 21.39%[4] - The net profit after deducting non-recurring gains and losses was RMB 231,475,776.61, which increased by 53.30% compared to the same period last year[4] - Basic and diluted earnings per share were both RMB 0.51, marking a 21.43% increase year-on-year[5] - Net profit for Q1 2024 was CNY 243,387,652.32, compared to CNY 200,972,272.94 in Q1 2023, reflecting an increase of approximately 21.0%[20] - Basic earnings per share for Q1 2024 were CNY 0.51, up from CNY 0.42 in Q1 2023, representing a growth of approximately 21.4%[21] Cash Flow - The net cash flow from operating activities was RMB 34,851,268.21, with a significant increase attributed to reduced expenses and employee bonuses[8] - In Q1 2024, the net cash flow from operating activities was 34,851,268.21, a significant improvement from -198,334,371.86 in Q1 2023[23] - Total cash inflow from operating activities was 1,380,453,113.82, compared to 1,524,539,434.51 in the same period last year, reflecting a decrease of approximately 9.4%[22] - Cash outflow from operating activities totaled 1,345,601,845.61, down from 1,722,873,806.37 in Q1 2023, indicating a reduction of about 21.9%[23] - The ending balance of cash and cash equivalents was 571,232,634.73, down from 1,106,405,377.17 at the end of Q1 2023, representing a decrease of approximately 48.3%[24] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,315,390,858.15, a decrease of 1.83% from the end of the previous year[5] - The company's total assets as of March 31, 2024, amounted to RMB 8,315,390,858.15, compared to RMB 8,470,008,293.83 as of December 31, 2023[16] - The company reported a total liability of CNY 1,188,057,942.06, down from CNY 1,486,581,550.49, indicating a decrease of approximately 20.0%[18] - The total equity attributable to shareholders increased to CNY 7,087,986,444.98 from CNY 6,944,100,603.15, a growth of about 2.1%[18] Research and Development - Research and development expenses totaled RMB 95,741,342.10, accounting for 7.04% of operating revenue, which is an increase of 0.67 percentage points from the previous year[5] - Research and development expenses rose to CNY 95,741,342.10 from CNY 83,153,130.85, marking an increase of about 15.5%[19] Shareholder Information - The top ten shareholders held a total of 58.86% of the shares, with the largest shareholder owning 283,500,000 shares[9] - As of April 26, 2024, the company has repurchased a total of 3,040,219 shares, accounting for 0.6312% of the total share capital of 481,678,242 shares, with a total expenditure of RMB 203,975,735.27[14] Government Support and Investments - The company received government subsidies amounting to RMB 11,028,362.09, which are closely related to its normal business operations[6] - The company received 7,139,138.96 in investment income, an increase from 4,737,573.13 in Q1 2023, reflecting a growth of about 50.7%[23] - The company has established strategic partnerships for investment in medical ventures, indicating a focus on expanding its healthcare investment portfolio[12] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[20]

证券代码：688363 证券简称：华熙生物 公告编号：2023-038 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 截至 2023 年 11 月 30 日，华熙生物科技股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 985,697 股，占公司总股本 481,678,242 股的比例为 0.2046%，回购成交的最高价 为 89.71 元/股，最低价为 70.96 元/股，支付的资金总额为人民币 77,122,249.86 元（不含印花税、交易佣金等交易费用）。 一、回购股份的基本情况 公司于 2023 年 8 月 29 日召开第二届董事会第八次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过集中竞价交 易方式进行股份回购，用于员工持股计划或者股权激励。公司拟用于本次回购的 资金总额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），回购价格为 不超过人民币 130 ...

证券代码：688363 证券简称：华熙生物 公告编号：2023-037 华熙生物科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 12 月 01 日(星期五) 至 12 月 07 日(星期四)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bloomagebiotech.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 华熙生物科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 31 日发 布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计划于2023年12月08日 上午 10:00-11:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2023 年第三季度的经营 成果及财务指标的具体情况与投资者进 ...

证券代码：688363 证券简称：华熙生物 公告编号：2023-036 华熙生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 截至 2023 年 10 月 31 日，华熙生物科技股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 434,367 股，占公司总股本 481,678,242 股的比例为 0.0902%，回购成交的最高价 为 89.71 元/股，最低价为 74.99 元/股，支付的资金总额为人民币 34,753,212.16 元（不含印花税、交易佣金等交易费用）。 一、回购股份的基本情况 公司于 2023 年 8 月 29 日召开第二届董事会第八次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过集中竞价交 易方式进行股份回购，用于员工持股计划或者股权激励。公司拟用于本次回购的 资金总额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），回购价 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥1,145,823,331.38, a decrease of 17.26% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥89,792,177.94, down 56.03% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥72,361,244.04, a decline of 61.53% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.19, a decrease of 55.81% year-on-year[5]. - The diluted earnings per share for Q3 2023 was also ¥0.19, reflecting a 55.81% decline compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2023 was approximately ¥4.22 billion, a decrease of 2.3% compared to ¥4.32 billion in the same period of 2022[21]. - Net profit for the third quarter of 2023 was approximately ¥507.08 million, down 24% from ¥667.16 million in the same quarter of 2022[25]. - Earnings per share for the third quarter of 2023 were ¥1.07, compared to ¥1.41 in the same quarter of 2022, reflecting a decrease of 24%[26]. - The total comprehensive income for the third quarter of 2023 was approximately ¥514.87 million, down from ¥658.76 million in the same quarter of 2022, a decrease of 21.8%[26]. Research and Development - The total R&D investment for the period was ¥90,408,566.44, a decrease of 7.56% year-on-year, with R&D expenses accounting for 7.89% of operating revenue, an increase of 0.83 percentage points[5]. - Research and development expenses remained stable at approximately ¥277 million for both years, indicating a consistent investment in innovation[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,349,563,535.99, a decrease of 3.83% compared to the end of the previous year[5]. - Current assets totaled RMB 3,207,373,119.40, down from RMB 4,023,100,101.48 in the previous year, reflecting a decline of about 20.2%[18]. - The company's cash and cash equivalents decreased from RMB 1,606,128,994.81 in December 2022 to RMB 1,127,091,845.15, a reduction of approximately 29.7%[18]. - The total liabilities decreased from approximately ¥1.99 billion in the previous year to ¥1.38 billion in the current year, a reduction of about 30.8%[22]. - The total equity attributable to shareholders increased to approximately ¥6.93 billion in 2023 from ¥6.63 billion in 2022, an increase of 4.4%[24]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥234,889,218.06, reflecting a significant increase of 101.64%[5]. - In the first three quarters of 2023, the cash inflow from operating activities was approximately CNY 4.68 billion, a decrease of 2.84% compared to CNY 4.82 billion in the same period of 2022[27]. - The net cash outflow from operating activities in the first three quarters of 2023 was CNY 234.89 million, an increase of 101.9% compared to CNY 116.49 million in the same period of 2022[28]. - The cash outflow from investing activities in the first three quarters of 2023 was CNY 1.85 billion, a decrease of 44.4% compared to CNY 3.33 billion in the same period of 2022[28]. - The total cash and cash equivalents at the end of Q3 2023 was CNY 692.96 million, down from CNY 748.01 million at the end of Q3 2022[29]. Share Repurchase - The company has repurchased a total of 95,456 shares, accounting for 0.0198% of the total share capital, with a total expenditure of RMB 8,388,185.94[16]. - The highest repurchase price was RMB 89.71 per share, while the lowest was RMB 86.41 per share[16]. - The company plans to use between RMB 200 million and RMB 300 million for share repurchase, with a maximum price of RMB 130.00 per share[16]. Other Financial Metrics - The weighted average return on equity for Q3 2023 was 1.35%, down 1.95 percentage points from the previous year[5]. - The company reported a decrease in tax expenses from approximately ¥152.23 million in 2022 to ¥103.34 million in 2023, a reduction of 32%[24]. - Other comprehensive income attributable to shareholders was approximately ¥7.79 million in 2023, compared to a loss of ¥8.40 million in 2022[25]. - The company experienced a negative impact of CNY 7.20 million from exchange rate fluctuations on cash and cash equivalents in Q3 2023[29]. - The company did not apply the new accounting standards starting in 2023, indicating a continuation of previous accounting practices[29].

(一) 审议通过《关于审议公司 2023 年第三季度报告的议案》 证券代码：688363 证券简称：华熙生物 公告编号：2023-035 华熙生物科技股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 2023 年 10 月 30 日，华熙生物科技股份有限公司（以下简称"公司"）于公 司会议室以现场结合通讯方式召开了第二届监事会第八次会议，会议通知已于 2023 年 10 月 25 日以电子邮件形式发出。本次会议由监事会主席于静女士主持， 应出席监事 3 人，实际出席并表决监事 3 人。会议的召开及程序符合《中华人民 共和国公司法》、《公司章程》及公司《监事会议事规则》的相关规定。 二、 监事会会议审议情况 表决结果：同意 3 票，反对 0 票，弃权 0 票。 监事会认为：公司 2023 年第三季度报告已经公司第二届董事会第九次会议 审议通过，其编制及审议程序符合法律、行政法规及中国证监会的规定，内容和 格式符合中国证监会和上海证券交易所的相关规定，所载资 ...

证券代码：688363 证券简称：华熙生物 公告编号：2023-034 华熙生物科技股份有限公司 关于控股股东无偿捐赠部分公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为纪念"中国透明质酸之父"山东大学张天民教授的崇高品格和杰出贡 献，感恩山东大学，激励齐鲁后学，支持山东大学在生物医药领域做出突出贡献 的学者和科研人员，促进中国生物科技产业的发展，华熙生物科技股份有限公司 （以下简称"华熙生物"、"公司"）近日收到公司实际控制人、董事长兼总经 理赵燕女士的通知，赵燕女士拟将其通过公司控股股东华熙昕宇投资有限公司 （以下简称"华熙昕宇"、"捐赠人"）间接持有的 4,816,782 股公司股份（以 下简称"标的股票"）捐赠给山东大学教育基金会（以下简称"受赠人"）（以 下简称"本次捐赠"）。本次捐赠的标的股票占公司总股本的比例为 1%。 截至本公告披露日，赵燕女士直接持有 115,920 股公司股份，占公司总 股本的比例为 0.02%；通过华熙昕宇间接持有 283,500,000 股公司股份， ...